{
    "id": "3507d3aa-6c7f-962d-e063-6294a90ae333",
    "indications": {
        "text": "metaxalone tablets indicated adjunct rest , physical therapy , measures relief discomfort associated acute , painful musculoskeletal conditions adults pediatric patients 13 years age older .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended metaxalone tablets adults pediatric patients 13 years age older 800 mg orally three four times day [ ( 8 ) ] . metaxalone tablets 800 mg substitutable mg mg basis metaxalone tablets , 640 mg [ pharmacology ( 12.3 ) ] . appropriate switch : switch patients taking metaxalone tablets , 640 mg empty stomach . stop metaxalone tablets , 640 mg three times day start metaxalone tablets 800 mg three times day empty stomach , stop metaxalone tablets 640 mg four times day start metaxalone tablets 800 mg four times day empty stomach . switch metaxalone tablets , 640 mg metaxalone tablets patient taking food .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "metaxalone tablets , usp available 800 mg capsule-shaped , scored white off-white tablet , inscribed \u201c 31 90 \u201d scored side \u201c wpi \u201d side . metaxalone tablets usp , 800 mg functional scoring . available follows . bottles 12 ndc 76420-898-12 ( repackaged ndc 0591-2341-01 ) . bottles 15 ndc 76420-898-15 ( repackaged ndc 0591-2341-xx ) . bottles 20 ndc 76420-898-02 ( repackaged ndc 0591-2341-xx ) . bottles 30 ndc 76420-898-03 ( repackaged ndc 0591-2341-xx ) . bottles 60 ndc 76420-898-06 ( repackaged ndc 0591-2341-xx ) . bottles 90 ndc 76420-898-09 ( repackaged ndc 0591-2341-xx ) . bottles 100 ndc 76420-898-01 ( relabeled ndc 0591-2341-01 ) . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "metaxalone tablets contraindicated patients : known hypersensitivity component metaxalone tablets . known tendency induced , hemolytic , anemias . severe renal hepatic impairment .",
    "ingredients": [
        {
            "name": "ALGINIC ACID",
            "code": "8C3Z4148WZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17548"
        },
        {
            "name": "AMMONIUM ALGINATE",
            "code": "Q9QKJ39Q3X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28938"
        },
        {
            "name": "CALCIUM ALGINATE",
            "code": "8P20S56HZI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_58187"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METAXALONE",
            "code": "1NMA9J598Y",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6797"
        }
    ],
    "organization": "Asclemed USA, Inc.",
    "name": "Metaxalone",
    "effectiveTime": "20250513",
    "indications_original": "Metaxalone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults and pediatric patients 13 years of age and older.",
    "contraindications_original": "The recommended dosage of metaxalone tablets in adults and pediatric patients 13 years of age and older is 800 mg orally three to four times a day\n \n   [see Use in Specific Populations (\n  \n    8)].\n \n   \n                     \n                  \n                  \n                     Metaxalone tablets 800 mg are not substitutable on a mg to mg basis with metaxalone tablets, 640 mg\n \n   [see Clinical Pharmacology (\n  \n    12.3)].\n \n   When it is appropriate to switch:\n\n  \n                  \n                  \n                     \n                        Switch only in patients who have been taking metaxalone tablets, 640 mg on an empty stomach.\n                     \n                     \n                        Stop metaxalone tablets, 640 mg three times a day and start metaxalone tablets 800 mg three times a day on an empty stomach, OR stop metaxalone tablets 640 mg four times a day and start metaxalone tablets 800 mg four times a day on an empty stomach.\n                     \n                  \n                  \n                     Do not switch from metaxalone tablets, 640 mg to metaxalone tablets when the patient is taking food during administration.",
    "warningsAndPrecautions_original": "Metaxalone tablets, USP are available as 800 mg capsule-shaped, scored white to off-white tablet, inscribed with \u201c \n  31 90\u201d on the scored side and \u201c \n  WPI\u201d on the other side. Metaxalone tablets USP, 800 mg has functional scoring.\n \n                  Available as follows.\n                  Bottles of 12  NDC 76420-898-12 (repackaged from NDC 0591-2341-01).\n                  Bottles of 15  NDC 76420-898-15 (repackaged from NDC 0591-2341-XX).\n                  Bottles of 20 NDC 76420-898-02 (repackaged from NDC 0591-2341-XX).\n                  Bottles of 30 NDC 76420-898-03 (repackaged from NDC 0591-2341-XX).\n                  Bottles of 60 NDC 76420-898-06 (repackaged from NDC 0591-2341-XX).\n                  Bottles of 90 NDC 76420-898-09 (repackaged from NDC 0591-2341-XX).\n                  Bottles of 100 NDC 76420-898-01 (relabeled from NDC 0591-2341-01).\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Metaxalone tablets are contraindicated in patients with:\n                  \n                     Known hypersensitivity to any component of metaxalone tablets.\n                     Known tendency to drug induced, hemolytic, or other anemias.\n                     Severe renal or hepatic impairment.",
    "drug": [
        {
            "name": "Metaxalone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6797"
        }
    ]
}